Pharmaceutical Industry Fellowship Program 2017

Leadership | Tradition | Motivation
Development | Dedication
The Rutgers Pharmaceutical Industry Fellowship Program has a long history at Novartis and offers a unique opportunity for recent Pharm.D. graduates to launch their career in the pharmaceutical industry. A wide selection of 2-year fellowships, across multiple departments, are offered at Novartis allowing fellows to focus in key areas during this post-graduate training program. We also provide a strong support network across the company that includes preceptors, fellowship group leaders, fellowship directors and program alumni. Our Pharm.D. fellows are often assigned to high priority projects allowing them to gain significant experience in the organization. Fellows are quickly integrated into their teams and as they matriculate through the program, successfully completing assigned projects, their responsibilities will continue to grow. This structure provides our fellows with a concentrated experience in their discipline of interest with accelerated growth driven by their talent and motivation.

Working closely with both fellows and preceptors over the years, I’ve observed firsthand how this program supports talent development and brings value to our organization. I’ve seen the talent and energy a Pharm.D. fellow can bring to their team. Past fellows that I’ve worked with have been involved with highly visible projects and have led strategic efforts directly impacting our business. I welcome you to consider the various fellowship positions at Novartis and wish you all the best throughout the candidate selection process.

**Shreeram Aradhye, M.D.**
Global Head, Development Franchise - Neuroscience
US Head, Development

"I’ve seen the talent and energy a Pharm.D. fellow can bring to their team."
When I started my career as a Post-Doctoral fellow at Novartis, I was seeking a fulfilling career in an untraditional pharmacy setting. The Rutgers Pharmaceutical Industry Fellowship exposed me to unique opportunities, provided me with lifelong mentors, an incredible network of colleagues and allowed me to build the foundation for my career in the pharmaceutical industry. Through the years I have remained a strong advocate for the Rutgers Pharmaceutical Industry Fellowship as a key vehicle for accelerated professional development.

I can attest that the broad background possessed by a Pharm.D. graduate is highly valued in our industry – and certainly here at Novartis. Established in 1990, the Novartis Fellowship is one of the longest standing programs within the Rutgers family of fellowships with over 150 fellows completing the program, signifying its strength and longevity. Each year, we set out to find the “best and the brightest” among the nation’s pharmacy doctoral programs. Novartis fellows consistently demonstrate the drive, self-motivation, and eagerness to learn and succeed within the various disciplines we offer, including early clinical development/translational medicine, clinical development, regulatory affairs, medical affairs, and commercial strategy/brand marketing.

I am enthusiastic about your interest in Novartis and wish you the best of luck during the challenging interview and application process.

Rob Kowalski, Pharm.D.
Head of Regulatory Affairs
Novartis
Fellow 1993-1995

Rob Kowalski was one of the first fellows in the original Sandoz (now Novartis) fellowship program from 1993-1995. He was recently appointed as Head of Regulatory Affairs for Novartis, Sandoz, and Alcon. Immediately prior to his return to Novartis, Rob was Vice President and Head of North America and Japan, Global Regulatory Affairs at Schering-Plough. Rob attended the University of Wisconsin–Madison where he received both a Bachelor of Science in Pharmaceutical Sciences and a Doctorate in Pharmacy.

"The broad background possessed by a Pharm.D. graduate is highly valued in our industry – and certainly here at Novartis."
Novartis Fellowship Program

Purpose
This two-year Post-Doctoral Pharmaceutical Industry Fellowship is designed to identify practice opportunities for pharmacists within Novartis through assignments that will build a depth of experience and enhance the potential for accelerated career development. Collectively, the fellowship is structured to provide a comprehensive post-doctoral experience.

Goal
As represented by the five values displayed on the cover, the Post-Doctoral Fellowship program demonstrates Novartis’ tradition in providing challenging growth opportunities to foster the development of highly-motivated and dedicated industry leaders.

Objectives
During the two-year program at Novartis, the fellow will:
• Gain a comprehensive overview of key areas within the pharmaceutical industry through practical insights and experiences
• Expand clinical knowledge through participation in both industrial and academic programs
• Promote the role and value of a clinically trained pharmacist within the pharmaceutical industry
• Actively participate in specific areas of industry and academia through direct involvement in various projects and assignments
• Become highly marketable for employment opportunities within the pharmaceutical industry
Novartis

Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide. Our portfolio focuses on broad areas of healthcare: pharmaceuticals, eye care, and generics.

Novartis Pharmaceuticals Corporation is headquartered in East Hanover, New Jersey, which is approximately 40 miles west of New York City. Novartis Pharmaceuticals Corporation represents the United States pharmaceutical business headquarters of the worldwide Swiss firm Novartis AG, which was formed in January 1997 following the merger of Ciba-Geigy Ltd. and Sandoz Ltd. Novartis Pharmaceuticals’ development efforts are focused in a number of therapeutic areas including: Cardio-Metabolic, Established Medicines, Immunology & Dermatology, Neuroscience, Oncology, Ophthalmology, and Respiratory.

As a global company, Novartis operates in 150 countries and employs approximately 118,000 people. In the United States alone, Novartis markets over 60 products which helped the company achieve global 2015 sales of $49.4 billion. That same year the company invested approximately $8.9 billion in research and development. Novartis is consistently rated as having one of the industry’s most respected development pipelines, with over 200 projects in clinical development. Novartis also had 14 major submissions and 20 major approvals in the United States, Europe, and Japan in 2015.

Novartis’ dedication to the discovery, development, manufacture, and marketing of innovative medications ensures that fellows will have in-depth exposure to key areas within the pharmaceutical industry.

A fellowship at Novartis affords fellows a tremendous opportunity to actively participate in all aspects of the drug development process.

The first year of the fellowship is typically dedicated to one of the departments described in this brochure. In the second year, fellows have the option to remain in the same department or transfer to another group elsewhere within Novartis.

Specific fellowship opportunities within departments vary depending on the interests of prospective candidates as well as the needs of Novartis.

In order to maximize their overall experience and to build a solid skill set, fellows may be presented with the opportunity to participate in special projects of interest. Fellows may also attend seminars and workshops designed to build professional skills such as time and project management, negotiation, and developing and delivering presentations. Opportunities to take internal training classes are also available. Fellows may be eligible to attend medical and professional conferences where they may present posters, participate in scientific sessions for continuing education credit, and network with colleagues.

Novartis fellows have the opportunity to participate in a three-month rotation either within or outside of Novartis. A broad range of opportunities are available, including clinical rotations at a university-affiliated hospital, the Ernest Mario School of Pharmacy, government agencies such as the US Food and Drug Administration or the National Institutes of Health, or other external vendors. Such rotations are structured to allow fellows to broaden their experience.

Our name, derived from the Latin novae artes, means “new skills” and reflects our commitment to bringing new healthcare products to patients and physicians worldwide.
Novartis Company Profile

Our Pharmaceuticals Business

The Pharmaceuticals Division of Novartis is recognized worldwide for the innovative medicines we provide to patients, physicians, and healthcare organizations. Our current product portfolio of prescription drugs includes more than 60 key marketed products, many of which are leaders in their respective therapeutic areas, among them Cardiology, Dermatology, Immunology, Neuroscience, Oncology, Ophthalmology and Respiratory.

Major Prescription Products†:

**Cardio-Metabolic**
- **Entresto™** (sacubitril and valsartan)
- **Galvus®** (vildagliptin)*

**Established Medicines**
- **Coartem®** (artemether and lumefantrine)
- **Comtan®** (entacapone)
- **Diovan®/Diovan HCT®** (valsartan/valsartan and hydrochlorothiazide)
- **Exforge®/Exforge HCT®** (amlodipine and valsartan, valsartan, hydrochlorothiazide)
- **Ritalin®/Ritalin LA®** (methylphenidate hydrochloride)
- **TOBI®/TOBI® Podhaler™** (tobramycin)
- **Voltaren®** (diclofenac sodium)

**Immunology & Dermatology**
- **Cosentyx™** (secukinumab)
- **Ilaris®** (canakinumab)
- **Myfortic®** (mycophenolic acid)
- **Neoral®** (cyclosporine)
- **Simulect®** (basiliximab)
- **Zortress®** (everolimus)

**Neuroscience**
- **Exelon®/Exelon® Patch** (rivastigmine)
- **Gilenya®** (fingolimod)

**Oncology**
- **Afinitor®** (everolimus)
- **Arzerra®** (ofatumumab)
- **Exjade®** (deferasirox)
- **Farydak®** (panobinostat)
- **Femara®** (letrozole)
- **Gleevec®** (imatinib mesylate)
- **Mekinist®** (trametinib)
- **Promacta®** (eltrombopag)
- **Sandostatin®** (octreotide acetate)
- **Tafinlar®** (dabrafenib)
- **Tasigna®** (nilotinib)
- **Zometa®** (zoledronic acid)
- **Zykadia™** (ceritinib)

**Ophthalmology**
- **Ilevro®** (nepafenac)
- **Lucentis®** (ranibizumab)
- **Nevanac®** (nepafenac)
- **Pazeo®** (olopatadine)
- **Simbrinz®** (brinzolamide/brimonidine tartrate)
- **Travatan Z®** (travoprost)

**Respiratory**
- **Arcapta™ Neohaler™** (indacaterol)
- **Ulbiron™ Neohaler®** (indacaterol/glycopyrrolate)
- **Xolair®** (omalizumab)

* Product not approved in the US.
† For statement of complete indications, please consult full prescribing information at www.pharma.us.novartis.com.

---

### 2015 Net Sales from Continuing Operations by Division

<table>
<thead>
<tr>
<th>Division</th>
<th>Net Sales (USD millions)</th>
<th>Growth in % cc</th>
<th>Divisional Share of Net Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceuticals</td>
<td>30 445/6%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcon</td>
<td>9 812/1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandoz</td>
<td>9 157/77%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*In constant currencies

---

### Performance Highlights

**Financial**

- **5%** Rise in net sales
- **9.0bn** Total free cash flow (USD)
- **10%** Increase in core operating income
- **73%** Increase in total net income (USD)

**Innovation**

- **200+** Projects in clinical development
- **8.9bn** Research and development spend (USD)

**Social**

- **66m** Patients reached through access programs
- **100%** Of top 20 conditions causing the global disease burden addressed by our portfolio

*In constant currencies and for continuing operations
2016 – 2017 Novartis Fellowship Program

Directors

**Angela Browne**
Global Program Regulatory Director
Regulatory Affairs
Respiratory
*B.S. Pharmacy*, Purdue University  
*Pharm.D.*, Purdue University  
Fellow 1999-2001

**Kudsia Hafeez**
Global Program Team Director
Cardio-Metabolic
*Pharm.D.*, Purdue University  
Fellow 2001-2003

Fellowship Coordinator

**Ginny Manfredi**
Senior Administrative Assistant
Regulatory Affairs
Respiratory
Novartis Fellowship Program Leadership Team

Group Leaders

**Nina Gutman Katz**
Director
Regulatory Affairs Oncology
*Pharm.D.*, Ernest Mario School of Pharmacy, Rutgers University
Fellow 2007-2009

**Christy Siegel**
Head, Strategy and Operations
Office of the President
Novartis Pharmaceuticals Corporation
*Pharm.D.*, Ernest Mario School of Pharmacy, Rutgers University
Fellow 2000-2001

**Jennifer Slade**
Global Senior Director, Medical Science Liaisons
Global Medical Affairs Oncology
*Pharm.D.*, Purdue University
Fellow 2000-2002

**Charlene Hall**
Lead Clinical Trial Head, Director
Clinical Development Oncology
*Pharm.D.*, University of Michigan
Fellow 2000-2002

**Alan J. Slade**
Clinical Scientific Director
Global Clinical Development Immunology & Dermatology
*Pharm.D.*, Purdue University
Fellow 2002-2004

**Lincy Thomas George**
Senior Director
Regulatory Affairs Oncology
*Pharm.D.*, Ernest Mario School of Pharmacy, Rutgers University
*M.B.A.*, Gabelli School of Business, Fordham University
Fellow 2003-2005

Leadership, Tradition, Motivation, Development, Dedication.
Early Clinical Development

Group Leader

Alan J. Slade
Clinical Scientific Director - Transplantation
Global Clinical Development
Immunology & Dermatology
Pharm.D., Purdue University
Fellow 2002-2004

Clinical Pharmacology/Translational Medicine Overview

Translational Medicine (TM) is a global, scientifically focused group which operates under the research arm of Novartis: the Novartis Institutes for BioMedical Research (NIBR). Scientists and clinicians within TM Clinical Sciences & Innovation (TM CS&I) and Translational Clinical Oncology (TCO) are primarily responsible for designing and conducting early phase clinical trials in healthy volunteers and patients. These trials explore and define the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and initial efficacy of small molecules, biologics, or cell-based therapies across numerous therapeutic areas, including oncology.

Fellowship opportunities are being offered in both TM CS&I (general and specialty medicine) and TCO (oncology). During their two-year fellowship:

- Fellows will be trained as a Clinical Trial Leader, coordinating all aspects of a clinical trial, which includes: writing clinical study protocol(s), designing case report forms (CRFs) and informed consent documents, selecting and initiating clinical sites, leading a clinical trial team, conducting investigator meetings, reviewing safety data, conducting dose escalation meetings, reporting and interpreting study results, as well as managing study timelines, drug supply, and study vendors.

- Fellows may also contribute to program-level activities, including the development of regulatory documents such as the Investigator's Brochure, briefing documents, annual safety reports, regulatory submission documents, study abstracts, posters, and meeting presentations.

- Fellows may have the opportunity to support or conduct one or more: first-in-human, proof-of-concept, dose-range finding, PK drug-interaction, and/or mechanistic profiling studies for novel therapeutics.
First-Year Fellows

Natalia Ceaicovscaia
Clinical Sciences and Innovation
Novartis Institutes for BioMedical Research
B.S. Molecular Biology, Biochemistry & Bioinformatics, Towson University
Pharm.D., University of Maryland School of Pharmacy

Sapna Chhagan
Translational Clinical Oncology
Novartis Institutes for BioMedical Research
B.S. Neurobiology, Physiology & Behavior, University of California, Davis
Pharm.D., Touro University California College of Pharmacy

“A Pharm.D. has the unique skill set to drive drug development from the lab to the patient.”
Clinical Development

Group Leader
Charlene Hall
Lead Clinical Trial Head, Director
Clinical Development
Oncology
Pharm.D., University of Michigan
Fellow 2000-2002

Clinical Development Overview

• Supports various aspects of a clinical trial during study startup, execution, or closeout.

• Supports global Phase II and III clinical trials, ensuring that trials are conducted in accordance with Novartis Standard Operating Procedures (SOPs) and Good Clinical Practice (GCP) standards as well as federal and other national regulations.

• Collaborates with Clinical Trial Head/Study Leads to coordinate activities of clinical trials teams to ensure goals are met for study timeline, budget, operational procedures, and quality standards.

• Interacts regularly with all members of the global clinical development teams and with other Novartis line functions (such as Drug Regulatory Affairs, Biostatistics, Data Management, Programming, Medical Writing, Drug Supply Management, and Clinical Operations) as a participant in the Global Clinical Trial Team.

• Supports Clinical Trial Head/Study Leads in development of study documents (protocols, protocol amendments, case report forms) and follows through regulatory procedures for “approval and implementation.”

• Supports Clinical Trial Head/Study Leads in operational procedures (country allocation, planning investigator meetings, managing drug supply, trial budget planning and management, and overseeing contract vendors) to ensure accuracy and consistency of trial deliverables.

• Contributes to ongoing review and supports trial analysis, reporting, and publishing.

• Assists with program level activities (such as development of clinical sections of regulatory documents, including Investigators’ Brochures, briefing books, safety updates, IND/NDA submission documents/Clinical Trial Applications (CTA), and responses to Health Authority questions).
"Pharm.D. fellows are able to apply their vast scientific knowledge in clinical development to meet unmet medical needs."
Regulatory Affairs

Group Leaders

Nina Gutman Katz
Director
Regulatory Affairs
Oncology
Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
Fellow 2007-2009

Lincy Thomas George
Senior Director
Regulatory Affairs
Oncology
Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
M.B.A., Gabelli School of Business, Fordham University
Fellow 2003-2005

Regulatory Affairs Overview

- Provides strategic input and tactical support to expedite the development, filing, and regulatory approval of new drug or biologic products.
- Interacts with cross-functional teams to develop, review, and approve product labeling as well as advertising and promotional materials.
- Files and maintains Investigational New Drugs (INDs), New Drug Applications (NDAs), Clinical Trial Applications (CTAs), and Marketing Authorization Applications (MAAs).

- Serves as primary liaison between Novartis and Regional Health Authorities – including the US Food and Drug Administration (FDA).
- Ensures compliance with national regulations and laws.
Second-Year Fellows

Alexandra Hendzel
Regulatory Affairs
Cardio-Metabolic
Pharm.D., Drake University
College of Pharmacy and Health Sciences
M.P.A., Drake University
College of Business and Public Administration

Dean Wetty
Regulatory Affairs
Established Medicines & Early Development
B.S. Pharmaceutical and Healthcare Studies, University of the Sciences
Pharm.D., Philadelphia College of Pharmacy, University of the Sciences

Rubin Modi
Regulatory Affairs
Oncology
B.S. Biochemistry, University of Waterloo
Pharm.D., Massachusetts College of Pharmacy and Health Sciences

First-Year Fellows

Amanda Bright
Regulatory Affairs
Oncology
Pharm.D., Ernest Mario School of Pharmacy, Rutgers University

Yekatsiaryna (Kate)
Kastsetskaya
Regulatory Affairs
Neuroscience
B.S. Chemistry/Spanish, Lake Forest College
Pharm.D., University of Illinois at Chicago College of Pharmacy

Mona Fassihi
Regulatory Affairs
Respiratory
Pharm.D., Temple University
School of Pharmacy
M.S. Regulatory Affairs & Quality Assurance, Temple University
School of Pharmacy

Jake Myhill
Regulatory Affairs
Immunology & Dermatology
Pharm.D., Massachusetts College of Pharmacy and Health Sciences
Medical Affairs

Group Leader

Jennifer Slade
Global Senior Director,
Medical Science Liaisons
Global Medical Affairs
Oncology
Pharm.D., Purdue University
Fellow 2000-2002

Medical Affairs Overview

As part of the Medical Affairs umbrella of disciplines, Scientific Communications, Medical Information, and Field Medical work together to provide an integrated medical communication platform for Novartis. Fellowship opportunities in Medical Affairs can include positions in the Novartis divisions of Pharmaceuticals and Oncology.

Scientific Communications is responsible for developing and disseminating scientific information on Novartis products through publications, medical education, and medical expert management.

Medical Information is responsible for using this scientific information to develop medical literature and drug information databases to research, evaluate, and develop evidence-based medical content for use by countries and regions to manage healthcare professional and customer interactions.

Field Medical personnel are responsible for establishing and maintaining relationships with healthcare professionals by engaging in scientific discussions regarding Novartis products, therapeutic areas of interest, and sponsored research.

Across these different roles, activities, and skills, there are opportunities to:

- Develop content and ensure the accuracy and scientific quality of manuscripts as well as abstracts, posters, and oral presentations of the latest clinical data at Novartis symposia, international congresses, and other educational programs.
- Develop internal global communications and education for Novartis products.
- Develop high-quality (relevant, rigorous, balanced) medical information documents for healthcare customers in response to unsolicited inquiries about Novartis products.
- Provide medical review of Novartis product materials in collaboration with a cross-functional team and communicate product information to healthcare professionals and customers.
Second-Year Fellows

**Rashaad Joseph**  
Global Scientific Communications  
Oncology  
Pharm.D., Florida A&M University  
College of Pharmacy and Pharmaceutical Sciences

**Ramya Mathew**  
Medical Information and Communication/Regulatory Affairs - Advertising & Promotion  
Pharm.D., St. John’s University  
College of Pharmacy and Health Sciences

**Zachary Post**  
US Field Medical  
Immunology & Dermatology  
Pharm.D., West Virginia University School of Pharmacy  
BCPS, PGY-1 Pharmacy Practice Residency, Louis Stokes Cleveland VA Medical Center

First-Year Fellows

**Pamela Gorczyca**  
Global Medical Information and Communications & Medical Science Liaison  
Oncology  
Pharm.D., St. John’s University  
College of Pharmacy and Health Sciences

**Gunjan Patel**  
US Scientific Communications  
Oncology  
B.S. Pharmacy Studies, Northeastern University School of Pharmacy  
Pharm.D., Northeastern University School of Pharmacy

**Galina Perel**  
US Medical Information and Communications  
Oncology  
Pharm.D., St. John’s University  
College of Pharmacy and Health Sciences

**Nehali Parikh**  
Medical Information and Communication/Regulatory Affairs - Advertising & Promotion  
Pharm.D., St. John’s University  
College of Pharmacy and Health Sciences
Commercial – Early Product Marketing and Business Development and Licensing (BD&L)

Group Leader

Christy Siegel
Head, Strategy and Operations
Office of the President
Novartis Pharmaceuticals Corporation
Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
Fellow 2000-2001

Commercial – Early Product Marketing and BD&L Overview

Note: This position will not be recruiting for the 2017 fellowship.

The fellow works in high performance, cross-functional disease area teams that drive US Pharma strategy. The primary objective is to deliver commercially meaningful pipeline brands to the US by identifying viable strategic options for the US market, providing recommendations to maximize US market opportunities including shaping Phase II and Phase III development programs, optimizing product profiles for successful launch and transitioning products to in-line commercial teams.

Roles and responsibilities of the fellow include:

• Drive development of Pipeline Strategic Planning (PSP) deliverables including situation analysis, options assessment, patient journey, target product profile, forecast and launch readiness plans.

• Participate in evaluation of business development & licensing opportunities, including scientific/clinical and commercial assessments and participate in due diligence of select opportunities.

• Scope and manage engagements with external vendors, such as custom epidemiology assessment or custom pricing research.

First-Year Fellow

Joe Britt
Early Products and Business Development & Licensing
US General Medicine
M.B.A., Clarkson University
Pharm.D., Albany College of Pharmacy
Novartis Fellowship Program Alumni

1990–1992
Mark Ammann
John Gladish

1991–1993
Irene Laurora
Bruce Robbins

1992–1994
Joseph Cordaro

1993–1995
Tracy Acker
Robert Kowalski
Sheri Thornberg

1994–1996
Veronica Valvano Benedetto
Beth Keibler
Taunia Markvicka

1995–1997
Michele Pongowski Ball
John Messina

1996–1998
Latifa Alladina
Branka Kowalski
Patricia Ledford
James Rawls

1997–1999
Soma Gupta
Sauzanne Khalilieh
Lisa Kutney
Henry Owunna
Maria Pryor
Katenka Svendsen Schumm

1998–2000
Kelley Piper Bradley
Kimberly Chappell
Lisa Malaty Ghaly
Lisa Pitt
Angela Sansone
Jane Chong Shen
Sheri Dranzo Siegel

1999–2001
Angela Browne
Kay Chitale
Shamita Gupta
Fonda Chen Liu
John Martin
Mandy McGuire
Scott Moren
Maria Moricz
Deepa Patel
Asli (Guven) Santos
Michelle Stolpman Tsai

2000–2002
Bryan Campbell
Bonnie Lieberman
Ariel Mihic
Lillian Ng
Monil Shah
Jennifer (Stolk) Slade
Charlene So
Susan Trieu
Andrea Viegas

2001–2003
Kevin Carl
Kimberly Dickerson
Kudsia Hafeez
Angela Liu
Ayanna (Abadie) Osson
Ram Palanki
Gar Park
Rick Satiltunwaycha

2002–2004
Telly Chi
Joseph A. Chiodo III
Darin Curtiss
Vanessa Foti Trainor
Celena Kwong
Laura B. Munir
Dat Nguyen
Alan Slade
Stephanie Tallon
Theresa Valdez

2003–2005
Payman Darouian
Harinder Dhillon
Michael Lu
Melissa (Pao) Mitchener
Stephen Mitchener
Todd Phillips
Lincy Thomas
Lotus Yung

2004–2006
Ira Do
Aaron Huang
Michelle Libner
Erika Massenburg
Felice Peng
Emily Scalise
Bijal Sheth
Lucio Volino

2005–2007
Amera Ali
Chyrin (Buu) Chung
Andy Hwang
Glendolynn Johnson
Amy (Patel) Shah

2006–2008
Melina Cioffi
Kathy Dong
Vanessa Kan
Suzanne Maahs
Melody M. Lee
Dale Nepert
Leslie Servidio
Chris Sung
Stephanie Whalen

2007–2009
Jonelle Chapman
Nina Gutman Katz
Shilpa Kurpad
John Noh
Kanan Solanki
Myah Tran
Bryan Zembrowski

2008–2010
Shazia Ali
Lhy Ping Lam
Vickie Laurent
Samuel Lee
Christopher Morrison
Dalal Nesheiwat
Hannah Mosca

2009–2011
Mercy Mathew Abraham
Katherine Carter
Brian Manning
Kimberly Mazzarisi Colligan
Bijal Pandhi
Puja (Patel) Geist
Arshdeep Pooni
Jessica Wang

2010–2012
Narim Ahmed
Associate Director
Drug Regulatory Affairs
Oncology
Novartis

2011–2013
Ira Do
Aaron Huang
Michelle Libner
Erika Massenburg
Felice Peng
Emily Scalise
Bijal Sheth
Lucio Volino

2013–2015
Ira Do
Aaron Huang
Michelle Libner
Erika Massenburg
Felice Peng
Emily Scalise
Bijal Sheth
Lucio Volino

2015–2017
Amera Ali
Chyrin (Buu) Chung
Andy Hwang
Glendolynn Johnson
Amy (Patel) Shah

2016–2018
Melina Cioffi
Kathy Dong
Vanessa Kan
Suzanne Maahs
Melody M. Lee
Dale Nepert
Leslie Servidio
Chris Sung
Stephanie Whalen

2017–2020
Narim Ahmed
Associate Director
Drug Regulatory Affairs
Oncology
Novartis

Breanne Donohue
Senior Manager
US Scientific Communications Oncology Novartis

Farah N. Hossain
Clinical Trial Head
Clinical Development Oncology Novartis

Nickie Gallaher
Product Manager
Managed Markets Launch Strategy Genentech

Drea Pangilinan
Manager
Medical Affairs Gilead Sciences

Manisha Patel
Associate Director
Drug Regulatory Affairs Oncology Novartis

Jiten Rana
Senior Associate Director
Drug Regulatory Affairs Oncology Novartis

Therese Swan
Senior Clinical Scientist
Clinical Sciences and Innovation Translational Medicine Novartis

Alex Wang
Pharmacist Meridian Health
**Novartis Fellowship Program Alumni**

**2011–2013**
- Robert Boothroyd
  - Associate Director
  - Global Scientific Communications
  - Oncology
  - Novartis
- Phillip Koo
  - Clinical Scientist
  - Clinical Science and Innovation
  - Translational Medicine
  - Novartis
- Doris Lo
  - Regulatory Affairs
  - Gilead Sciences
- TanTan (Liza) Ng
  - Clinical Trials Manager
  - Gilead Sciences
- Demetre Stamatis
  - Associate Director
  - Drug Regulatory Affairs
  - Oncology
  - Novartis
- Allison Upalawanna
  - Clinical Trial Head
  - Clinical Development
  - Oncology
  - Novartis

**2012–2014**
- Madee Dhawan
  - Global Indication Lead
  - Multiple Myeloma
  - Novartis
- Beth Drimalla
  - Associate Director
  - US Medical Information, Payer
  - Oncology
  - Novartis
- Melissa Kuhn
  - Clinical Scientist Associate
  - Product Development
  - Oncology
  - Genentech
- Jeremy Lim
  - Associate Clinical Scientist
  - Early Development, Immunology and Infectious Diseases
  - Genentech
- Melissa Neighbors
  - US Regulatory Lead
  - Regulatory Affairs
  - Amgen
- Joanne Nguyen
  - Medical Science Liaison
  - Cardiovascular
  - Boehringer Ingelheim
- Michelle Pernice
  - Senior Manager & EU Regulatory Lead
  - Regulatory Affairs
  - Amgen
- Lincoln Rogers
  - Medical Science Liaison
  - Oncology
  - AstraZeneca
- Marilyn Tsourounis
  - Associate Director
  - Global Labeling Strategy, Oncology
  - Regulatory Affairs
  - AstraZeneca

**2013–2015**
- Jenna Konkel
  - Medical Science Liaison
  - US Medical - Neuroscience
  - Novartis
- Lisa White Krueger
  - Senior Regulatory Manager
  - Drug Regulatory Affairs
  - Oncology
  - Novartis
- Brigette Nezami
  - Senior Manager
  - US Scientific Communications
  - Oncology
  - Novartis
- Tuong Vi Nguyen
  - Expert Clinical Manager
  - Clinical Development
  - Oncology
  - Novartis
- Hetal Pansuria
  - Manager
  - Regulatory Affairs
  - Pacira Pharmaceuticals
- Jennifer Poon
  - Senior Associate
  - Regulatory Affairs
  - BioMarin Pharmaceutical
- Maryam Shirmohamadali
  - Clinical Trial Manager
  - Gilead Sciences
- Matt Temer
  - Clinical Trial Manager
  - Gilead Sciences
- Iris Wang
  - Senior Manager
  - US Scientific Communications
  - Oncology
  - Novartis

**2014–2016**
- Geetha Pudussery
  - Senior Clinical Manager
  - Oncology
  - Novartis
- Viraj Degaonkar
  - Clinical Scientist Associate
  - Genentech
- Ashley Brower
  - Global Program Manager
  - Regulatory Affairs
  - Immunology & Dermatology
  - Novartis
- Naomi Kozlowski
  - US Lead
  - Regulatory Affairs
  - Amgen
- Anisha Baghat
  - Manager
  - Global Medical Affairs
  - Intercept Pharmaceuticals
- Julia Hautman
  - Medical Science Liaison
  - Respiratory
  - Teva
- Priya Ramachandran
  - Manager
  - Global Medical Information and MSL
  - Oncology
  - Novartis
Rutgers Pharmaceutical Industry Fellowship Program

Program History
In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 19 companies within the pharmaceutical and biopharmaceutical industries and over 160 fellows annually.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the Institute for Pharmaceutical Industry Fellowships to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Provide leadership and administrative support;
- Promote quality, communication, and scholarly activity; and
- Arrange specialized fellowship training opportunities within the pharmaceutical and biopharmaceutical industries.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor II of the Ernest Mario School of Pharmacy and Dr. Michael Toscani, Research Professor and the Fellowship Director for the Institute for Pharmaceutical Industry Fellowships.

Joseph A. Barone
Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy

Michael Toscani
Pharm.D.
Research Professor,
Fellowship Director
Institute for Pharmaceutical Industry Fellowships
More than 850 post-doctoral fellows have completed the RPIF Program, most of whom are pursuing influential and rewarding careers in the pharmaceutical and biopharmaceutical industries throughout the US and abroad. The RPIF Program has preceptors/mentors from the industry who share their knowledge and experiences with the fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industries and the fellow's functional area.

**Professional Development Series**

All fellows gather at Rutgers once or twice monthly as a group to participate in the Professional Development Day (PDD) Series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of fellows and are designed to enhance the fellows’ presentation skills, emotional intelligence, promote connectivity and a sense of community among fellows from different companies and disciplines, develop new skill sets under the guidance of external trainers, and provide general knowledge about various aspects of drug development and issues facing the pharmaceutical and biopharmaceutical industries.

The fellows learn from each other through individual and group presentations and debates on topics and issues related to the pharmaceutical and biopharmaceutical industries. This dynamic forum provides an opportunity for open discussion and debate among fellows, Rutgers faculty, and company preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success; professional writing, presentations, meeting facilitation, negotiating, influencing, networking, and conflict resolution skills; giving and receiving feedback; and business and dining etiquette). Other PDD guest speakers include senior industry executives, patient advocacy groups, and successful RPIF Program alumni who share their insights and experiences. Importantly, PDDs provide an excellent opportunity for fellows to interact with each other and develop lasting personal friendships and a strong professional network of fellows, faculty, alumni, and other industry executives.
Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program FOSTERs the growth and development of future pharmaceutical and biopharmaceutical industry professionals through the following key program features:

FAMILY OF LEADING COMPANIES – Partners include several of the top 19 global pharmaceutical and biopharmaceutical companies.

OUTSTANDING ALUMNI TRACK RECORD – Over 850 alumni hold prominent positions at many leading companies.

STRONG NETWORK – Over 160 fellows each year develop valuable, lasting connections with each other, alumni, preceptors and faculty.

THE PATHWAY TO INDUSTRY – Since 1984, the Rutgers program has been nationally recognized, trusted, and proven as the pathway to industry for pharmacists.

ENHANCED CAREER PATH – Increasingly challenging assignments build depth of experience and enhance the potential for an accelerated career path.

STRICTLY ACADEMIC COMPONENT – Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with approximately 65,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy is the only state school of pharmacy in New Jersey, with approximately 1,400 students in its Doctor of Pharmacy program.

The Rutgers Ernest Mario School of Pharmacy is located on the University’s main science and technology campus in Piscataway, New Jersey. Because of its close proximity to the nation’s leading pharmaceutical and biopharmaceutical companies, the Ernest Mario School of Pharmacy and the RPIF Program are uniquely capable of providing fellows with exposure to the pharmaceutical and biopharmaceutical industries.

Application Process and Eligibility Requirements:

Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally-competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE accredited institution before July 1 of the fellowship term.

Participation in the ASHP Midyear Clinical Meeting/PPS is strongly encouraged. Interested individuals are invited to electronically submit a curriculum vitae, three letters of recommendation and a letter of intent and complete a program interest form online by visiting our website at: pharmafellows.rutgers.edu

Please address all correspondence to:
Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020
ifellows@pharmacy.rutgers.edu

Application materials may be submitted as early as November 19, and applicants are encouraged to submit as many of the required materials as possible by December 15.